Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
189,947,836
-
Number of holders
-
106
-
Total 13F shares, excl. options
-
37,117,728
-
Shares change
-
+7,685,268
-
Total reported value, excl. options
-
$315,928,313
-
Value change
-
+$59,335,508
-
Put/Call ratio
-
54%
-
Number of buys
-
66
-
Number of sells
-
41
-
Price
-
$8.49
Institutional Holders of Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share (WVE) as of Q3 2020
As of 30 Sep 2020 Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share (WVE) had 106 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 37,117,728 shares of stock of the company.
Largest 10 holders included RA CAPITAL MANAGEMENT, L.P., PRIMECAP MANAGEMENT CO/CA/, Bellevue Group AG, PERCEPTIVE ADVISORS LLC, BlackRock Inc., Nantahala Capital Management, LLC, JPMORGAN CHASE & CO, MORGAN STANLEY, Alyeska Investment Group, L.P., and PRICE T ROWE ASSOCIATES INC /MD/.
This table shows 106 institutional shareholders of the security as of 30 Sep 2020.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.